Silo Pharma, Inc. (SILO) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Silo Pharma, Inc. is a developmental-stage biopharmaceutical company with a cryptocurrency treasury strategy. The company focuses on developing novel therapeutics for PTSD, anxiety, fibromyalgia, and CNS diseases (including Alzheimer's and Multiple Sclerosis). In April 2026, the company formed a subsidiary, Qwikagentsai Inc., to diversify into AI technology. On June 2, 2026, the company effectuated a 1-for-15 reverse stock split.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $18,026 | $36,051 |
| Net Loss | $(2,479,946) | $(2,235,730) |
| Net Loss Per Share (Basic/Diluted) | $(2.46) | $(6.22) |
| Cash and Cash Equivalents (End of Period) | $3,277,095 | $4,333,672 |
| Short-Term Investments | $1,950,147 | $2,110,065 |
| Working Capital | $4,647,793 | $6,737,542 |
| Cash Used in Operating Activities | $(1,604,484) | $(2,925,568) |
| Accumulated Deficit | $(21,972,335) | $(17,500,421) |
Material Changes vs. Prior Period
- Revenue Cessation: Revenue dropped to $18,026 for the six months ended June 30, 2026, compared to $36,051 in the prior year. Effective April 1, 2026, the company ceased recognizing license fee revenues from its agreement with Aikido Pharma Inc. due to the expiration of the underlying University of Maryland, Baltimore (UMB) Master License. Remaining deferred revenue of approximately $703,552 was reclassified to a liability titled "contingently returnable sublicense fee."
- Operating Expenses: Total operating expenses increased slightly to $2.52 million from $2.38 million year-over-year. This was driven by a $714,000 non-cash expense related to the acquisition of AI software assets (Many Ads Inc.) recorded as R&D, offset by a decrease in R&D costs from third-party vendors.
- Crypto Asset Volatility: The company recorded an unrealized loss of $89,143 on crypto assets held at fair value and an impairment loss of $29,911 on crypto assets held at cost during the period. Conversely, a gain on debt settlement of $91,645 contributed to other income.
- Capital Structure: The company completed a 1-for-15 reverse stock split in June 2026. Shares outstanding increased from 887,886 to 1,128,610 during the period due to stock issuances for services and technology acquisitions.
Guidance, Outlook, and Risks
- Liquidity and Financing: Management believes current cash and short-term investments are sufficient to meet obligations for at least twelve months. This outlook is supported by a July 2026 Private Placement (subsequent event) which raised approximately $4.0 million in gross proceeds ($3.5 million net).
- Strategic Shifts: The company is actively pursuing a cryptocurrency treasury strategy and has diversified into AI via the Qwikagentsai subsidiary. The biopharmaceutical pipeline remains focused on SPC-15 (PTSD/Anxiety), SP-26 (Fibromyalgia), SPC-14 (Alzheimer's), and SPU-16 (Multiple Sclerosis).
- Risks: Key risks include the need for additional financing to fund operations and clinical trials, the uncertainty of clinical trial outcomes, regulatory hurdles for psychedelic and novel therapeutics, and volatility in cryptocurrency valuations. The company has an accumulated deficit of nearly $22 million.
- Stock Repurchase: A $1 million stock repurchase plan was approved in February 2026. As of June 30, 2026, no shares had been repurchased, though a subsequent repurchase of 6,015 shares occurred in July 2026.
Investor Verification Checklist
- Revenue Sustainability: Verify the status of the "contingently returnable sublicense fee" liability and whether the company has secured new licensing agreements to replace the terminated Aikido/UMB revenue stream.
- Crypto Asset Valuation: Review the specific composition and fair value methodology of the $205,414 in crypto assets, given the significant unrealized losses recorded in the period.
- Cash Burn Rate: Assess the runway provided by the $3.27 million cash balance and the $3.5 million net proceeds from the July 2026 offering against the $1.6 million operating cash burn for the six-month period.
- AI Acquisition Integration: Evaluate the strategic fit and potential monetization of the $714,000 AI software acquisition (Qwikagentsai) relative to the core biopharmaceutical business.
- Reverse Stock Split Impact: Confirm the trading volume and liquidity of the stock post 1-for-15 reverse split to ensure continued compliance with Nasdaq listing standards.